precision-fermentation
(18)
Bel Group
How a Jura cheesemaker became a 120-country snacking machine - and why a 160-year-old family business is now spending it on regenerative farms and lab-made dairy.
Ajikumar Parayil
He spent years teaching bacteria to build molecules that used to take entire fields of plants. Then he bet a company on getting those microbes out of the lab and into million-liter tanks.
Helaina
Helaina is a New York-based biotechnology company using precision fermentation to produce human-equivalent bioactive proteins. Its first commercial product, effera, is a human-identical lactoferrin made in yeast that matches the amino acid sequence of the protein found in mother's milk. Founded in 2019 by food scientist Laura Katz, Helaina sells effera as a B2B ingredient to consumer wellness and supplement brands, targeting women's health, gut health, active nutrition and healthy aging. The company has raised roughly $84 million in equity funding, including a $45 million Series B in 2024.
Manus
Manus (Manus Bio) is an MIT-born industrial biotechnology company that engineers microbial cell factories and precision fermentation to produce natural ingredients - sweeteners, flavors, fragrances and pharmaceutical building blocks - that are normally extracted from plants or made from petrochemicals. Branded as 'The BioAlternatives Company,' Manus runs an R&D hub in Boston and a commercial-scale biomanufacturing plant in Augusta, Georgia, where it makes products such as monk fruit sweetener and stevia Reb M for partners including Givaudan and Tate & Lyle.
Laura Katz
Laura Katz is the founder and CEO of Helaina, a New York biotech company that uses precision fermentation to produce human-identical bioactive proteins. Its first product, effera, is the world's first commercially available human lactoferrin made through yeast fermentation. A food scientist by training and once NYU's youngest adjunct professor in Food Science, Katz started the company in 2019 from her Lower East Side kitchen after hearing a podcast about the black market for breast milk. She has raised more than $80 million to move Helaina from research into a commercial ingredient business.
Circe
Circe (Circe Bioscience) is a Boston-based climate biotech company that engineers microbes to eat carbon dioxide and build valuable molecules - fats, oils, sugars, plastics and fuels - using only CO2, water and electricity. Spun out of Harvard's Wyss Institute in 2021, its gas-fermentation platform consumes roughly 3 kilograms of CO2 for every kilogram of oil it produces, making the process carbon-negative. The company has made the world's first chocolate using fermentation-derived cocoa butter and, in September 2024, raised a $5M seed round to open a pilot plant in Waltham, Massachusetts.
Fengru Lin
Fengru Lin is the co-founder and CEO of TurtleTree, a biotech company making dairy proteins without cows. A former Google account manager who took up cheesemaking as a hobby, she went hunting across Asia for clean raw milk, was horrified by what she found on the farms, and started a company to make milk in a lab instead. TurtleTree pivoted from full cell-cultured milk to precision fermentation, and now produces lactoferrin, a high-value milk protein once called 'pink gold,' using microbes instead of herds. She has raised roughly $44 million and made EDGE's 35 Under 35 and Her World's Young Woman Achiever lists.
Shannon Nangle
Shannon Nangle is a microbe-wrangling scientist turned CEO who co-founded Circe Bioscience to make fats, oils, and even chocolate out of thin air. Her company feeds carbon dioxide, water, and electricity to engineered microbes that grow like plants and excrete valuable molecules, producing food and industrial ingredients in a carbon-negative way. Spun out of Harvard's Wyss Institute in 2021, Circe made what it calls the world's first gas-fermentation-derived chocolate and has raised over $17 million to scale a manufacturing process Nangle spent six years building.
Solarbiotech
Solarbiotech is a U.S.-based synthetic biology and biomanufacturing company that helps companies move precision-fermentation products from lab bench to commercial scale. Built around a Norton, Virginia plant with fermentation capacity from 6L to 10,000L and a modular 'BioNodes' architecture, it offers end-to-end strain-to-shelf services - upstream fermentation, downstream processing, and commercial production - for food ingredients, nutraceuticals, cosmetics, enzymes, and industrial bioproducts. After a 2024 Chapter 11 restructuring, its assets were acquired by Pictor Biotech (led by ex-Novozymes executive Peter Rosholm) and unified in January 2025 with GPC Bio and Eleszto Genetika into a vertically integrated, 100+ person SynBio platform.
Eric Abbate
Eric Abbate is a synthetic-biology scientist turned CEO who led Solar Biotech, a Virginia-based startup building solar-powered, water-neutral fermentation plants to make biodesigned cosmetics, food ingredients and bioelectronic components. A UC Berkeley-trained molecular and cell biologist, he ran high-throughput genome-engineering and analytical biochemistry teams at Inscripta and was corresponding author on a widely cited paper on optimizing strain engineering for industrial-scale production. He steered Solar Biotech from lab science toward a modular 'BioNodes' manufacturing model before the company entered Chapter 11 in 2024 with plans to sell its assets and reboot.
Meijie Wang
Meijie Wang is the co-founder and CEO of MetaNovas, an AI-driven biotech that designs functional peptides for skincare, supplements and drug discovery. A former NVIDIA AI infrastructure engineer who built VR games and worked on AI at Stanford's School of Medicine, he now runs a Silicon Valley and Shanghai operation whose knowledge-graph platform aims to compress the decade-long hunt for new bioactive ingredients into something far shorter. MetaNovas counts L'Oreal, Beiersdorf, Haleon, Takeda and Unilever among its partners and raised a Series A led by GL Ventures.
Triplebar
Triplebar is an Emeryville, California biotech company that pairs a high-throughput microfluidic screening platform with AI genomic models to run evolution at hyper-speed. By packing tens of millions of picoliter microreactors onto a palm-sized chip and testing thousands per second, it generates matched genotype-phenotype datasets that let partners optimize cell lines and microbial strains far faster and cheaper than conventional lab work. The platform powers products across food (precision fermentation, cultivated meat) and biopharma (biologics, cell-engaging cancer therapies).
TurtleTree
TurtleTree is a biotech and food-tech company that makes lactoferrin - one of the rarest and most valuable proteins in cow's milk - without the cow. Using precision fermentation, its flagship ingredient LF+ recreates the bioactive milk protein at scale for use in immunity, gut health, sports nutrition and infant nutrition products. In 2025 TurtleTree became the first company in the world to win an FDA 'No Questions' GRAS letter for precision-fermented lactoferrin, clearing it to commercialize in the U.S.
Shawn Manchester
Shawn Manchester is the CEO of Triplebar, an Emeryville-and-Oakland based biotech building generative AI 'genome language models' paired with ultra-high-throughput phenotypic screening to slash the cost of biologic therapeutics and food proteins. A chemical engineer by training (BS Brown, PhD MIT), he was the lead scientist in the first AI-versus-human strain engineering contest at Zymergen before joining Triplebar in 2021, where he rose from VP of Product to COO to CEO in March 2025.
Ryan Pandya
Ryan Pandya co-founded Perfect Day in 2014 with the audacious goal of making dairy without cows. Using precision fermentation, the Berkeley-based biotech raised nearly $800 million, built partnerships with Fortune 500 food companies, and proved that animal-free whey protein could reach global markets across dozens of product categories. After a decade at the helm, Pandya stepped down as CEO at the end of 2023 to pursue future ventures, leaving behind a company that had fundamentally shifted the conversation around sustainable dairy.
Perfect Day
Perfect Day is a Berkeley-based food-tech company that brews real dairy whey protein with microbes instead of cows. Using precision fermentation in steel tanks, it produces ProFerm - a beta-lactoglobulin identical to the protein in milk - and sells it as a B2B ingredient to food brands building animal-free ice cream, cream cheese, protein powders and beverages.
The EVERY Company
The EVERY Company is a San Francisco Bay Area biotech that uses precision fermentation to brew real egg proteins (ovalbumin, pepsin, and more) without chickens. Its ingredients - OvoPro, EVERY Egg White, and EVERY Protein - power baked goods, beverages, and protein bars sold by food brands ranging from startups to multinationals.
Arturo Elizondo
Arturo Elizondo is the co-founder and CEO of The EVERY Company (formerly Clara Foods), the precision fermentation biotech pioneering animal-free egg proteins used by food brands worldwide. Born in Laredo, Texas, educated at Harvard, and seasoned by stints at the White House, USDA, and Credit Suisse, he co-founded the company in 2014 after meeting a cell biologist at a food-tech conference. Under his leadership, EVERY has raised over $471M, launched the world's first animal-free egg protein into Walmart, attracted actress Anne Hathaway as an investor, and earned Elizondo the EY Entrepreneur of the Year 2023 Bay Area Award. His mission: end factory farming by making fermentation-derived proteins cheaper, cleaner, and better than the real thing.